🌸 Allergy Immunotherapy Vaccine Tracker Dashboard

Updated July 2026. The allergy immunotherapy field continues to advance both traditional allergen-specific immunotherapy (subcutaneous SCIT, sublingual SLIT) and next-generation approaches. Palforzia (peanut oral immunotherapy) remains FDA-approved for ages 4–17. Neffy (epinephrine nasal spray, ARS Pharmaceuticals) was FDA-approved August 2024 as the first needle-free epinephrine for severe allergic reactions. Recent focus areas include: mRNA-based allergen tolerance induction (preclinical), biologics as adjuncts (omalizumab FDA-approved Feb 2024 for food allergy reactions in age 1+), and epicutaneous immunotherapy (Viaskin Peanut patch – DBV Technologies).

Comprehensive tracking of allergy immunotherapy development including SLIT (sublingual) tablets, SCIT (subcutaneous) allergy shots, peptide vaccines, and next-generation tolerance approaches. Allergies affect 100 million US adults (40%), 400 million globally. Allergic rhinitis (hay fever), asthma, food allergies, and eczema cause significant morbidity and $18 billion annual US costs. Immunotherapy induces immune tolerance to allergens through gradual desensitization, offering long-term symptom relief and potential cure. Multiple FDA-approved SLIT tablets (grass, ragweed, dust mite), injectable SCIT formulations, and novel peptide/recombinant vaccines in development. Disease-modifying treatment changing natural history vs. symptomatic medications. Complementary to environmental control and antihistamines.